Crinetics Pharma secures EMA approval for Palsonify (paltusotine) for acromegaly.
Crinetics Pharmaceuticals has secured European marketing authorisation for Palsonify (paltusotine), its oral, once-daily therapy for acromegaly. This approval introduces a significant non-injectable option into a market long dominated by monthly injections. It directly challenges the established treatment protocol.
Drug Profile
Palsonify (paltusotine) is a nonpeptide, small-molecule somatostatin receptor type 2 (SST2) agonist. Unlike existing peptide-based somatostatin analogues (SSAs) that require injection, paltusotine was designed for oral bioavailability. Its structure allows it to bind selectively to the SST2 receptor, mimicking the natural inhibitory effects of somatostatin on growth hormone (GH) secretion from the pituitary gland. This mechanism reduces circulating levels of both GH and insulin-like growth factor 1 (IGF-1), the key drivers of acromegaly pathology. The drug's design as a small molecule overcomes the gastrointestinal degradation that prevents peptide-based SSAs from being administered orally.
Clinical Data
The EMA approval was supported by efficacy and safety data from two Phase 3 trials, PATHFNDR-1 and PATHFNDR-2.
| Endpoint | Result | Comparator (Placebo) | Trial | | --------------------------------------------------------------------- | ------ | -------------------- | ----------- | | Proportion of patients maintaining IGF-1 response (≤1.0 x ULN) | 83% | 4% | PATHFNDR-1 | | Proportion of patients achieving IGF-1 response (≤1.0 x ULN) | 56% | 5% | PATHFNDR-2 |
*(Source: Crinetics Pharmaceuticals PATHFNDR-1 & PATHFNDR-2 Topline Results Announcements)*
Global Regulatory Status
Drug-specific status across all four regulatory bodies BrunoSan tracks. Separate from pipeline volume shown in the infobar.
| Regulatory Body | Status | Notes |
|---|---|---|
| Agency | Status | |
| FDA (U.S.) | NDA submitted; PDUFA target date anticipated in H2 2026. | |
| EMA (EU) | ✓ Approved 2026-05-06 | |
| HC (Canada) | No submission entry detected in BrunoSan DB as of 2026-05-06. | |
| ANVISA (Brazil) | No submission entry detected in BrunoSan DB as of 2026-05-06. |
STATUS
Market Impact
The approval of Palsonify in Europe directly targets the market share of long-acting injectable (LAI) SSAs, primarily Novartis’s Sandostatin LAR (octreotide) and Ipsen’s Somatuline Depot (lanreotide). These LAIs represent the current standard of care but impose a significant treatment burden, requiring monthly deep subcutaneous or intramuscular injections often administered by healthcare professionals. Palsonify’s once-daily oral administration offers a substantial improvement in patient convenience, which could drive rapid adoption, particularly among patients experiencing injection-site reactions or seeking greater autonomy over their treatment regimen.
The commercial success of Palsonify will depend on its ability to overcome the market inertia that has protected LAIs. Chiasma’s Mycapssa, another oral SSA, has seen modest uptake since its approval, demonstrating the challenge of converting patients and physicians from a long-established injectable standard. Crinetics may have an advantage with Palsonify's once-daily dosing and lack of food-effect restrictions, which simplifies the regimen compared to Mycapssa. Payer acceptance and pricing strategy will be critical; demonstrating non-inferiority to LAIs on efficacy while offering superior convenience will be the core value proposition for securing favorable reimbursement and displacing entrenched competitors.
Based on BrunoSan pipeline data tracking 2,193 cumulative EMA entries, Palsonify's approval is consistent with a broader regulatory trend favoring oral formulations in chronic diseases previously managed by injectables. This shift prioritizes patient quality of life and adherence. The staggered regulatory timeline, with EMA approval preceding a potential FDA decision, is a common pattern observed across our database of 14,314 global regulatory events. This creates an initial market test bed in Europe while U.S. market access remains the primary value driver.
The key determinant for Palsonify's market penetration will be its ability to demonstrate a clear advantage over both LAIs and the existing oral competitor, Mycapssa. While the convenience of an oral pill is a powerful motivator, physician prescribing habits in the acromegaly space are deeply ingrained. Crinetics' commercial strategy must focus on educating endocrinologists about the PATHFNDR data and highlighting the simplified once-daily regimen. The U.S. PDUFA date in H2 2026 is the next critical catalyst that will define the drug's global commercial trajectory.